CinFina Pharma Presents Positive Phase 1 Study Results in Poster Session for CIN-109 and in Late-Breaking Poster for CIN-110, Demonstrating the Potential of Next-Generation Mechanisms at ObesityWeek® 2024 Read More November 3, 2024
CinFina Pharma to Present Posters Demonstrating the Potential of New Mechanisms at ObesityWeek® 2024 Read More October 23, 2024
CinFina Pharma Announces Initiation of Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of CIN-110 for the Treatment of Obesity Read More July 30, 2024
CinFina Pharma Announces FDA Clearance of Investigational New Drug Application and First Participants Dosed in Phase 1 Trial of CIN-110 for the Treatment of Obesity Read More March 26, 2024
CinPhloro Pharma, A CinRx Portfolio Company, Dosed First Participant in Phase 2 enviva Study of CIN-103 for IBS-D Read More February 22, 2024
CinFina Pharma, a CinRx Portfolio Company, Introduces Scientific Advisory Board with Deep Metabolic Expertise Read More December 14, 2023
CinRx Portfolio Company CinDome Pharma Presents Encouraging Data on Deudomperidone (CIN-102) at 2023 Digestive Disease Week® Conference Read More May 8, 2023
CinRx’s CinDome Pharma to Present a Poster on Deudomperidone (CIN-102) at 2023 Digestive Disease Week® Conference Read More May 2, 2023
CinRx Pharma Announces First Participant Dosed in CinDome’s Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis Read More April 27, 2023
